Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.
|Titolo:||High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy|
LA VECCHIA, CARLO VITANTONIO BATTISTA (Penultimo)
|Parole Chiave:||Administration, Oral; Ovarian Neoplasms; Antineoplastic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Adult; Aged; Middle Aged; Medroxyprogesterone; Medroxyprogesterone Acetate; Female|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
|Data di pubblicazione:||dic-1981|
|Digital Object Identifier (DOI):||10.1016/0090-8258(81)90131-1|
|Appare nelle tipologie:||01 - Articolo su periodico|